Las Vegas, NV – August 12, 2025 – Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging technology company developing healthcare solutions, and its Joint Venture partner, Ainnova Tech, Inc. (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that Ainnova is refining its patient recruitment strategy for the Company’s planned clinical trial for its Vision AI platform in the early detection of diabetic retinopathy. Ainnova will work directly with Fortrea, a globally recognized Contract Research Organization (CRO) renowned for its expertise in ophthalmology studies and medical device trials, following the guidance the Company received from its recent meeting with the U.S. Food and Drug Administration (FDA).
The planned clinical study, which will be performed in 8-10 clinical sites around the U.S., will prioritize the recruitment of approximately 1,000 multiethnic patients, with a focus on individuals living with diabetes. By targeting community clinics and primary care facilities rather than specialized ophthalmology centers, Ainnova aims to capture real-world data that reflects the diverse population affected by diabetic retinopathy. This strategic approach ensures the study aligns with the practical realities of diabetes care, providing robust and relevant data to support the Company’s FDA 510(k) submission.
“We are excited to move forward with an enhanced patient recruitment process,” said Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio. “By focusing on community clinics and targeting a multiethnic group of around 1,000 diabetic patients, we aim to ensure that our study accurately represents the diverse population affected by diabetic retinopathy.
“Working with Fortrea, an expert CRO in ophthalmology, allows us to confidently navigate this process with a partner that shares our commitment to quality and efficiency. We are getting closer to initiating a clinical study that will significantly contribute to obtaining FDA 510(k) approval and making our Vision AI platform a crucial tool in early disease detection.”
Ainnova’s collaboration with Fortrea underscores its commitment to conducting a rigorous and inclusive clinical study. By leveraging Fortrea’s deep expertise in ophthalmology and medical device trials, Ainnova is well-positioned to deliver high-quality data to support the regulatory approval process to market Vision AI, a platform poised to transform early disease detection for diabetic patients worldwide, in the United States.
AAC has the worldwide licensing rights for Ainnova’s technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova’s clinical trial is paramount to marketing the technology portfolio in the United States . Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.
About Ainnova Tech, Inc.
Ainnova is a Nevada -based healthtech startup with headquarters in San Jose, Costa Rica , and Houston, Texas . Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
In other Biotech/Big Pharma Developments of note:
Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives recently announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder.
“We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage,” said David Hallett, Chief Scientific Officer of Recursion. “Having full ownership of this important program allows Recursion to accelerate the development of the first potential oral disease-modifying treatment to HPP patients, who currently face significant challenges with limited access to existing therapies. While this is a preclinical asset that will require further study, we look forward to leveraging the full power of the Recursion OS to gain even deeper insights and accelerate delivery of the potential treatment.”
BioXcel Therapeutics, Inc. (NASDAQ: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, reported its financial results for the second quarter of 2025 and announced that its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia was complete. Topline results from the study are expected in August.
“We are incredibly excited about the upcoming top-line data readout for our SERENITY At-Home Phase 3 trial – our primary market research and preliminary results regarding the frequency of agitation episodes during the trial suggest a target addressable market meaningfully larger than our original estimate of 23 million agitation episodes in the at-home setting annually,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “This expanded opportunity estimate presents a significant prospect to help many bipolar disorder and schizophrenia patients, fulfilling our core mission.”
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc., President and CEO: Naoki Okamura, “Astellas”) announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). The EV-303 study is evaluating PADCEV
(enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment (before and after surgery) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy.
At the first interim efficacy analysis, the trial demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS), the study’s primary endpoint, and overall survival (OS), a key secondary endpoint, with neoadjuvant and adjuvant PADCEV plus KEYTRUDA versus surgery alone. An additional secondary endpoint of pathologic complete response (pCR) rate was also met.
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov ). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.
SOURCE Avant Technologies Inc.
At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies. #tickertagpressreleases #pressreleases
Follow us on Facebook to receive the latest news updates: https://www.facebook.com/financialnewsmedia
Follow us on Twitter for real time Market News: https://twitter.com/FNMgroup
Follow us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
The post Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial appeared first on Financial News Media.
